 PLYMOUTH MEETING, Pa., April 12, 2021 PRNewswire -- Harmony Biosciences Holdings, Inc. Harmony Nasdaq: HRMY, a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced that results from two analyses from the clinical development program for WAKIX pitolisant will be presented at the 2021 American Academy of Neurology AAN Annual Meeting, to be held virtually April 17-22. 